GlassScriptPhysician profile
Joseph C Lin
NPI 1801810601
$13,490.41
in general payments reported to CMS, 2019-2025
26 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,622 · 2020: $672 · 2021: $2,929 · 2022: $1,334 · 2023: $1,138 · 2024: $1,229 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,843.58 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,786.11 | 2019-2025 | Vemlidy, Livdelzi, Epclusa |
| Abbvie INC. | $1,430.39 | 2019-2025 | |
| Celgene Corporation | $424.53 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $423.22 | 2022-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $373.74 | 2024-2025 | Rezdiffra |
| Pfizer INC. | $239.25 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $234.87 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $200.20 | 2024-2025 | Ibsrela |
| Allergan, INC. | $188.91 | 2019 | |
| Phathom Pharmaceuticals, INC. | $169.75 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $144.63 | 2019-2023 | Ocaliva |
| Kerecis Limited | $138.47 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Novo Nordisk INC | $126.30 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $120.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2023 | Zeposia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $75.87 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $62.06 | 2019 | |
| Braintree Laboratories, INC. | $45.42 | 2020-2024 | Suflave, Sutab |
| Qol Medical, LLC | $34.40 | 2019 | |
| Sunovion Pharmaceuticals INC. | $30.80 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.69 | 2019-2020 | |
| Redhill Biopharma INC. | $30.15 | 2021 | |
| Organon LLC | $19.27 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.76 | 2022 | |
| Mauna Kea Technologies, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.